arrow
R

Romain Banchereau

Genentech
H指数:38
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma

高-risk 局部肾细胞癌配对的原发和复发肿瘤的全面基因组学和转录组学特征

2026-04-250
PRE
Aryl hydrocarbon receptor restrains tonic cytokine responses by inhibiting microbiota sensing in monocytes

芳基烃受体通过抑制单核细胞对微生物的感知来抑制持续的细胞因子反应。

2025-12-011
OA
Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer
2024-02-0113
OAAI
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (vol 25, pg 1706, 2019)
2023-03-210
OA
LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity

LRRC15肌成纤维细胞决定基质设定点以抑制肿瘤免疫

Nature
IF48.5
2022-09-280
OAAI
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
2022-08-0182
OA
Molecular determinants of response to PD-L1 blockade across tumor types
2021-06-2591
OAAI
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade (vol 26, pg 693, 2020)
2021-02-055
OAAI
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (vol 25, pg 1706, 2019)
2020-05-151
OAAI
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

高全身和肿瘤相关IL-8与PD-L1阻断的临床获益降低相关

2020-05-11283
OAAI
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

ABACUS试验中阿特珠单抗新辅助治疗可手术尿路上皮癌的临床疗效和生物标志物分析

2019-11-04415
OAAI